Patient of the Month: Frankie


Published on: 12/04/2017

What was supposed to be a fun day for Frankie and his sister with their uncle quickly took an unexpected and tragic turn. Frankie was kicked in the head by a horse at the ranch they were visiting, and he suffered a traumatic brain injury. He was airlifted to the nearest trauma center, and as soon as he was stable, his parents opted to have him transferred via LifeFlight to Nicklaus Children’s Hospital. Today, he is getting better by the day thanks to the care he received at Nicklaus Children’s.

Read Previous Read Next

Related News

Caring for Matthew: Managing a Very Rare Disease

April 03, 2025 – Matthew was diagnosed with Phelan-McDermid Syndrome (PMS), a rare genetic disorder that affects development, speech, and cognitive ability, and requires extensive medical care and round-the-clock support. Despite his challenges, Matthew radiates love and joy, and his family is advocating for increased awareness of PMS while seeking potential treatments for the condition.

Luigi's Journey Toward a Better Tomorrow

March 31, 2025 – Luigi's parents faced fear and uncertainty when their son was diagnosed with Lennox-Gastaut syndrome and severe seizures at six months old. Thanks to the compassionate care and innovative treatments at Nicklaus Children’s Hospital, Luigi has made remarkable progress, and his family has opened a PPEC facility to support other families navigating similar challenges.

Leading Pediatric Epilepsy Care for 40 Years

February 26, 2025 – For 40 years, Nicklaus Children's Hospital has been a leader in pediatric epilepsy. Learn more about the comprehensive care we offer for the most complex chronic cases.

Gene Therapy Offers New Hope for Children with Duchenne MD

January 23, 2025 – At Nicklaus Children's Hospital, gene therapy offers a promising treatment that dramatically improves life for children with Duchenne muscular dystrophy. Recognizing the potential wielded by a new gene therapy, Nicklaus Children’s became one of the first in the nation to offer ELEVIDYS-dystrophin soon after the FDA's 2023 approval.